Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

1. Wave Life Sciences reports lower stock prices due to Phase 1b/2a data release. 2. GSK holds exclusive global license for RNA-editing drug WVE-006. 3. WVE-006 shows potential for treating alpha-1 antitrypsin deficiency. 4. Data indicates a favorable safety profile for WVE-006 treatment. 5. Development and commercialization will transfer to GSK post-study completion.